Payment overview · 2025
General Payments
$52,185.69
48 reported records · 6 companies
Healthcare provider profile · identity verified
Tabitha Grace Moe, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · PHOENIX, AZ · NPI 1508067588
Verified facts
What the public records show
CMS Open Payments records show Tabitha Grace Moe, M.D. received $52,185.69 in general payments during 2025 across 48 reported records.
Novo Nordisk Inc accounted for 85.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Opsumit, Ozempic, Uptravi, Wegovy.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPSUMIT as an associated drug or biological on 18955 records involving 8899 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Opsumit by this doctor in 2024.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UPTRAVI as an associated drug or biological on 21562 records involving 9341 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Uptravi by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 320 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 320 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $44,431.86 | 85.1% | 24 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $4,534.11 | 8.7% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $1,650.00 | 3.2% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$1,326.17 | 2.5% | 14 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $138.11 | 0.3% | 4 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $105.44 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $49,060.06 | 19 |
| Travel and Lodging | $1,611.16 | 7 |
| Food and Beverage | $1,514.47 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $33,599.01 | 17 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $6,184.11 | 5 | 2025 |
Source payment records
|
|||||
| HARMONY Normalized: harmony |
Device | Medtronic, Inc. | $1,326.17 | 14 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $138.11 | 4 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $131.14 | 3 | 2025 |
Source payment records
|
|||||
| THE EDWARDS SAPIEN 3 VALVE WITH ALTERRA ADAPTIVE PRESTENT SYSTEM Normalized: the edwards sapien 3 valve with alterra adaptive prestent system |
Device | Edwards Lifesciences Corporation | $105.44 | 1 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $6.97 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $4.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 320 | exact normalized | Medicare Part D |
| OPSUMIT opsumit |
2025 | Opsumit | 2024 | 67 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 129 | exact normalized | Medicare Part D |
| UPTRAVI uptravi |
2025 | Uptravi | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | OPSUMIT open payments reported associated product |
CMS Open Payments — General Payments 18955 supporting records · 8899 recipient NPIs · example record 1174163978 |
Opsumit · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | UPTRAVI open payments reported associated product |
CMS Open Payments — General Payments 21562 supporting records · 9341 recipient NPIs · example record 1174163984 |
Uptravi · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
320 | 111 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
320 | 111 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
63 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
129 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 593 | 203 |
| Amlodipine Besylate | Amlodipine Besylate | 459 | 150 |
| Eliquis | Apixaban | 440 | 125 |
| Metoprolol Succinate | Metoprolol Succinate | 425 | 136 |
| Losartan Potassium | Losartan Potassium | 409 | 146 |
| Jardiance | Empagliflozin | 320 | 111 |
| Carvedilol | Carvedilol | 308 | 95 |
| Metoprolol Tartrate | Metoprolol Tartrate | 292 | 94 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 272 | 90 |
| Lisinopril | Lisinopril | 255 | 87 |
| Furosemide | Furosemide | 224 | 85 |
| Ozempic | Semaglutide | 129 | 24 |
| Spironolactone | Spironolactone | 126 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 122 | 48 |
| Entresto | Sacubitril/Valsartan | 122 | 32 |
| Xarelto | Rivaroxaban | 116 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 96 | 38 |
| Simvastatin | Simvastatin | 94 | 31 |
| Ezetimibe | Ezetimibe | 88 | 31 |
| Warfarin Sodium | Warfarin Sodium | 83 | 21 |
| Amiodarone Hcl | Amiodarone Hcl | 82 | 27 |
| Repatha Sureclick | Evolocumab | 79 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 69 | 22 |
| Opsumit | Macitentan | 67 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 63 | 24 |
| Mounjaro | Tirzepatide | 63 | 15 |
| Praluent Pen | Alirocumab | 58 | suppressed |
| Sotalol | Sotalol Hcl | 57 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 54 | 17 |
| Potassium Chloride | Potassium Chloride | 53 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | 15 |
| Atenolol | Atenolol | 46 | 16 |
| Valsartan | Valsartan | 46 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | 18 |
| Clonidine | Clonidine | 42 | 12 |
| Levothyroxine Sodium | Levothyroxine Sodium | 41 | 13 |
| Clonidine Hcl | Clonidine Hcl | 37 | 18 |
| Nifedipine Er | Nifedipine | 36 | suppressed |
| Bumetanide | Bumetanide | 35 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 28 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 26 | suppressed |
| Metolazone | Metolazone | 26 | suppressed |
| Uptravi | Selexipag | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 16 |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Tadalafil | Tadalafil | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Wegovy | Semaglutide | 17 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 14 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Metformin Hcl | Metformin Hcl | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Adempas | Riociguat | 12 | suppressed |
| Allopurinol | Allopurinol | 12 | suppressed |
| Ambrisentan | Ambrisentan | 12 | suppressed |
| Camzyos | Mavacamten | 12 | suppressed |
| Omeprazole | Omeprazole | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $52,185.69 · 48 records | Novo Nordisk Inc | HARMONY, JARDIANCE, OPSUMIT, OPSYNVI, Ozempic, THE EDWARDS SAPIEN 3 VALVE WITH ALTERRA ADAPTIVE PRESTENT SYSTEM, UPTRAVI, Wegovy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Actelion Pharmaceuticals US, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error